Momenta Pharmaceuticals, now a member of the Janssen Pharmaceutical companies of Johnson & Johnson, specializes in developing novel therapies for patients with rare immune-mediated diseases. The company focuses on neurology, hematology, and maternal-fetal medicine, addressing conditions such as Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hemolytic Disease of the Fetus and Newborn (HDFN), Idiopathic Thrombocytopenic Purpura (ITP), and Warm Autoimmune Hemolytic Anemia (wAIHA).

Momenta operates in the biopharmaceutical market, serving patients, healthcare providers, and medical researchers. The business model revolves around extensive research and development (R&D) to create groundbreaking treatments, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the sale of these specialized therapies, often in collaboration with larger pharmaceutical entities like Johnson & Johnson.

The company is driven by a mission to overcome the 'impossible,' taking on challenges that few are brave enough to tackle. This ethos is reflected in their innovative approach and willingness to take risks in order to make a real impact on patients' lives.

Keywords: rare diseases, immune-mediated, neurology, hematology, maternal-fetal medicine, biopharmaceutical, R&D, clinical trials, innovative therapies, Johnson & Johnson.